致死率高，尼帕病毒席卷印度！我国科研团队有新发现

Group 1: Nipah Virus Overview - The Nipah virus, with a mortality rate ranging from 40% to 75%, has re-emerged in West Bengal, India, raising international concern [1][2] - Recent reports indicate five cases of Nipah virus infection in West Bengal, including healthcare workers, leading to nearly 100 individuals being quarantined [2] - Since 2001, India has experienced multiple outbreaks of the Nipah virus, with a total of 754 confirmed cases and 435 deaths across five countries, including India and Bangladesh, as of May 2024 [3] Group 2: Health Monitoring and Response - Thailand and Nepal have intensified health monitoring and quarantine measures for travelers from India, while China has included Nipah virus in its entry monitoring protocols [4] - The Chinese Academy of Sciences has announced the discovery of an oral antiviral drug, VV116, which shows significant efficacy against the Nipah virus in animal studies [5][6] Group 3: Diagnostic and Testing Developments - Several Chinese companies have developed and disclosed testing kits for the Nipah virus, including PCR nucleic acid test kits with high sensitivity [10][11] - Companies like ZhiJiang Biology and Shuoshi Biology have provided testing kits to customs and disease control agencies to aid in monitoring and prevention efforts [10][11] Group 4: Market Reactions - Following the news of the Nipah virus outbreak, the A-share market saw a surge in the vaccine and in vitro diagnostic (IVD) sectors, with many stocks hitting the daily limit up, although there was a significant pullback the following day [12]